All In Biotech

Drug Trial Radar · NCT00457860

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)

Last checked: Nov 20, 2026Latest source record: Apr 17, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Actual

Start

Mar 2007

Primary completion

Not stated

Sponsor

Lead sponsor
Cambridge Antibody TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 9, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have chronic lymphocytic leukemia, prolymphocytic leukemia or small lymphocytic lymphoma that has not responded to treatment

Conditions

  • Leukemia

Interventions

  • Immunotoxin therapyDrug

  • CAT-8015 immunotoxinDrug

  • Biological therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate the maximum dose that can be safely administered to a patient
  2. Characterize the toxicity profile of CAT-8015
  3. Study the clinical pharmacology of CAT-8015
  4. Observe anti-tumor activity, if any

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California · Recruiting

  • Indiana University Cancer Center

    Indianapolis, Indiana · Not yet recruiting

  • Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office

    Bethesda, Maryland · Recruiting

  • Klinika Hemtologii Uniwersytetu Medycznego (Medical University of Lodz)

    Lodz, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.